CRISPR-based detection enables highly specific molecular recognition
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Subscribe To Our Newsletter & Stay Updated